Mardiza, Rosemalyn L.
HRN: 22-23-72 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/22/2022
CEFUROXIME 500MG (TAB)
11/22/2022
11/29/2022
PO
500mg
BID X 7 Days
UTI; Pus Cells: 8-10; Bacteria: Abundant
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes